These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 33820810)

  • 21. uPAR
    Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
    Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
    Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.
    Abdel-Wahab N; Diab A; Yu RK; Futreal A; Criswell LA; Tayar JH; Dadu R; Shannon V; Shete SS; Suarez-Almazor ME
    Cancer Immunol Immunother; 2021 Jul; 70(7):1939-1949. PubMed ID: 33409738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predominant CD8
    Tominaga K; Toda E; Takeuchi K; Takakuma S; Sakamoto E; Kuno H; Kajimoto Y; Terasaki Y; Kunugi S; Mii A; Sakai Y; Terasaki M; Shimizu A
    Pathol Int; 2024 Jun; 74(6):317-326. PubMed ID: 38634742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
    Blum SM; Rouhani SJ; Sullivan RJ
    Immunol Rev; 2023 Sep; 318(1):167-178. PubMed ID: 37578634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic disease and adverse events from immune checkpoint inhibitors.
    Leiter A; Carroll E; De Alwis S; Brooks D; Shimol JB; Eisenberg E; Wisnivesky JP; Galsky MD; Gallagher EJ
    Eur J Endocrinol; 2021 Jun; 184(6):857-865. PubMed ID: 34552304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
    Olsson Ladjevardi C; Koliadi A; Rydén V; Inan El-Naggar A; Digkas E; Valachis A; Ullenhag GJ
    Cancer Med; 2023 Jun; 12(12):13217-13224. PubMed ID: 37132258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
    van Eijs MJM; Verheijden RJ; van der Wees SA; Nierkens S; van Lindert ASR; Suijkerbuijk KPM; van Wijk F;
    Cancer Immunol Immunother; 2023 Dec; 72(12):4049-4064. PubMed ID: 37794264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF in the era of immune checkpoint inhibitors: friend or foe?
    Chen AY; Wolchok JD; Bass AR
    Nat Rev Rheumatol; 2021 Apr; 17(4):213-223. PubMed ID: 33686279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors.
    Gulati N; Celen A; Johannet P; Mehnert JM; Weber J; Krogsgaard M; Osman I; Zhong J
    Cancer Med; 2021 Nov; 10(21):7457-7465. PubMed ID: 34647433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
    Kao CJ; Charmsaz S; Alden SL; Brancati M; Li HL; Balaji A; Munjal K; Howe K; Mitchell S; Leatherman J; Griffin E; Nakazawa M; Tsai HL; Danilova L; Thoburn C; Gizzi J; Gross NE; Hernandez A; Coyne EM; Shin SM; Babu JS; Apostol GW; Durham J; Christmas BJ; Konig MF; Lipson EJ; Naidoo J; Cappelli LC; Pabani A; Ged Y; Baretti M; Brahmer J; Hoffman-Censits J; Seiwert TY; Garonce-Hediger R; Guha A; Bansal S; Tang L; Jaffee EM; Chandler GS; Mohindra R; Ho WJ; Yarchoan M
    J Clin Invest; 2024 Aug; 134(20):. PubMed ID: 39403935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
    Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.